Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00199290
Status:
COMPLETED
Last Update Posted:
2008-02-05
First Post:
2005-09-12
Brief Title:
A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan
Sponsor:
Kaken Pharmaceutical
Organization:
Kaken Pharmaceutical
Study Overview
Official Title:
A Phase 2 Randomized Double Blind Placebo-Controlled Parallel Group Study to Evaluate the Efficacy and the Safety of Trafermin in Patients With Marginal Periodontitis in Japan
Status:
COMPLETED
Status Verified Date:
2008-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to evaluate the efficacy and the safety of Traferminrecombinant human basic fibroblast growth factor rhbFGF in Japanese patients with marginal periodontitis in order to verify the superiority of Trafermin to placebo and to determine the recommended therapeutic dose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None